CYRAMZA (ramucirumab), monoclonal antibody

»  CYRAMZA has Marketing Authorisation in treatment of advanced gastric cancers or gastro-oesophageal junction adenocarcinoma, having progressed after platinum salt- and/or fluoropyrimidine-based chemotherapy, in combination with paclitaxel or in monotherapy when paclitaxel is not indicated.

»  In combination with paclitaxel compared with paclitaxel alone, the median overall survival was slightly longer (+2.3 months) with an increase in adverse effects.

»  In monotherapy, its actual benefit is insufficient to justify its reimbursement due to a negligible clinical benefit.